Literature DB >> 20708407

Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.

Shintaro Suzuki1, Kasthuraiah Maddali, Chie Hashimoto, Emiko Urano, Nami Ohashi, Tomohiro Tanaka, Taro Ozaki, Hiroshi Arai, Hiroshi Tsutsumi, Tetsuo Narumi, Wataru Nomura, Naoki Yamamoto, Yves Pommier, Jun A Komano, Hirokazu Tamamura.   

Abstract

Structure-activity relationship studies were conducted on HIV integrase (IN) inhibitory peptides which were found by the screening of an overlapping peptide library derived from HIV-1 gene products. Since these peptides located in the second helix of Vpr are considered to have an alpha-helical conformation, Glu-Lys pairs were introduced into the i and i+4 positions to increase the helicity of the lead compound possessing an octa-arginyl group. Ala-scan was also performed on the lead compound for the identification of the amino acid residues responsible for the inhibitory activity. The results indicated the importance of an alpha-helical structure for the expression of inhibitory activity, and presented a binding model of integrase and the lead compound. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708407      PMCID: PMC4486254          DOI: 10.1016/j.bmc.2010.07.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  17 in total

1.  In vitro human immunodeficiency virus type 1 integrase assays.

Authors:  C Marchand; N Neamati; Y Pommier
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

2.  A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity.

Authors:  Hua Yan; Tomoko Chiba Mizutani; Nobuhiko Nomura; Tadakazu Takakura; Yoshihiro Kitamura; Hideka Miura; Masako Nishizawa; Masashi Tatsumi; Naoki Yamamoto; Wataru Sugiura
Journal:  Antivir Chem Chemother       Date:  2005

3.  Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones.

Authors:  Elena A Semenova; Allison A Johnson; Christophe Marchand; David A Davis; Robert Yarchoan; Yves Pommier
Journal:  Mol Pharmacol       Date:  2006-01-17       Impact factor: 4.436

4.  The barrier-to-autointegration protein is a host factor for HIV type 1 integration.

Authors:  H Chen; A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro.

Authors:  C M Farnet; F D Bushman
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

6.  Possible existence of common internalization mechanisms among arginine-rich peptides.

Authors:  Tomoki Suzuki; Shiroh Futaki; Miki Niwa; Seigo Tanaka; Kunihiro Ueda; Yukio Sugiura
Journal:  J Biol Chem       Date:  2001-11-15       Impact factor: 5.157

7.  HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other.

Authors:  T Tasara; G Maga; M O Hottiger; U Hübscher
Journal:  FEBS Lett       Date:  2001-10-19       Impact factor: 4.124

8.  Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase.

Authors:  H Leh; P Brodin; J Bischerour; E Deprez; P Tauc; J C Brochon; E LeCam; D Coulaud; C Auclair; J F Mouscadet
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

9.  Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins.

Authors:  Eric A Hehl; Pheroze Joshi; Ganjam V Kalpana; Vinayaka R Prasad
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).

Authors:  Iris Oz Gleenberg; Alon Herschhorn; Amnon Hizi
Journal:  J Mol Biol       Date:  2007-04-01       Impact factor: 5.469

View more
  5 in total

Review 1.  HIV integrase inhibitors: 20-year landmark and challenges.

Authors:  Mathieu Métifiot; Christophe Marchand; Yves Pommier
Journal:  Adv Pharmacol       Date:  2013

2.  Cell-permeable stapled peptides based on HIV-1 integrase inhibitors derived from HIV-1 gene products.

Authors:  Wataru Nomura; Haruo Aikawa; Nami Ohashi; Emiko Urano; Mathieu Métifiot; Masayuki Fujino; Kasthuraiah Maddali; Taro Ozaki; Ami Nozue; Tetsuo Narumi; Chie Hashimoto; Tomohiro Tanaka; Yves Pommier; Naoki Yamamoto; Jun A Komano; Tsutomu Murakami; Hirokazu Tamamura
Journal:  ACS Chem Biol       Date:  2013-08-15       Impact factor: 5.100

3.  Inhibiting the HIV integration process: past, present, and the future.

Authors:  Roberto Di Santo
Journal:  J Med Chem       Date:  2013-09-25       Impact factor: 7.446

4.  Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins.

Authors:  Takuya Kobayakawa; Masaru Yokoyama; Kohei Tsuji; Masayuki Fujino; Masaki Kurakami; Sayaka Boku; Miyuki Nakayama; Moemi Kaneko; Nami Ohashi; Osamu Kotani; Tsutomu Murakami; Hironori Sato; Hirokazu Tamamura
Journal:  Biomolecules       Date:  2021-02-03

Review 5.  Development of peptide inhibitors of HIV transmission.

Authors:  Siyu Shi; Peter K Nguyen; Henry J Cabral; Ramon Diez-Barroso; Paul J Derry; Satoko M Kanahara; Vivek A Kumar
Journal:  Bioact Mater       Date:  2016-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.